Tuesday May 26, 2020 0 comments
ENGLEWOOD -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, announced it is developing therapies for patients infected with the SARS-CoV-2 virus (COVID-19).
Ampio said it has filed Investigative New Drug applications for Ampion with the FDA and has maintained ongoing dialog with the FDA regarding the company's development of treatment options, which includes inhalation and intravenous applications for COVID-19 affected patients.
Ampio said years of extensive in-vitro studies on cell cultures have confirmed that the mechanism of action of Ampion may be suitable for the treatment of inflammatory conditions, such as acute respiratory distress syndrome and the cytokine storm, associated with COVID-19.
Many of these research related findings have been published in peer reviewed, scientific journals, which can be found on the company's website, Ampio said.